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 Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease 
across the world. Once it progresses to non-alcoholic steatohepatitis (NASH), little can be 
done to reverse the damage. A potential treatment for NASH is cannabigerol (CBG), as it has 
shown anti-inflammatory effects in other models, although, little is known about its effects 
on NASH. Mast cells (MCs) play a role in mediating the progression of NASH. Their 
concentration in the liver directly correlates to levels of fibrosis. Therefore, we aim to 
evaluate levels of MC infiltration under CBG treatment in a NASH-induced mouse model. 
C57BL/6 mice were fed with a methionine/choline-deficient (MCD) or control (CTR) diet 
for 3 weeks, then divided into 3 sub-groups. The mice were injected with vehicle, low CBG 
[2.46 mg/kg/day], or high CBG [24.6 mg/kg/day] for another two weeks. The livers were 
harvested and frozen to be sliced for placement on slides. Slides were stained for presence of 
MCs using Toluidine-blue (T-blue) stain and Naphthol A-SD chloroacetate-esterase (CAE) 
stain. The samples were observed under a microscope and evaluated for mast cell infiltration. 
Co-staining of FcɛR1 (a MC biomarker) and TGFβ1 (a pro-inflammatory cytokine) was used 
to stain the co-localization of MCs and their inflammatory effect using immunofluorescence. 
We have found that treatment with low CBG decreased the numbers of MCs in MCD mice 
while high CBG treatment did not. There was no positive staining of MCs in the control 
groups. These results are consistent with the FcɛR1/TGFβ1 immunofluorescence staining. 
There was no positive staining for mast cells in the control groups and treatment with low 
CBG decreased the presence of mast cells and TGFβ1 expression. In conclusion, low CBG 
treatment reduced MC infiltration caused by the MCD diet in the mice. High CBG treatment 
did not reduce MC infiltration in the mice.   
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 As the prevalence of obesity and type 2 diabetes increases in Western culture, so does 
the risk of developing non-alcoholic fatty liver disease (NAFLD), the most common chronic 
liver disease worldwide (Yu, 2018). Non-alcoholic steatohepatitis (NASH) is the advanced 
stage of NAFLD, followed by potential fibrosis and cirrhosis or cryptogenic cirrhosis, which 
can develop into hepatocellular carcinoma (HCC), at which point a liver transplant is 
required (Yu, 2018). Following the development of NASH, chances of cardiovascular 
mortality increase, leaving the medical community searching for treatment methods (Sanyal, 
2011). While beginning stages of NAFLD can be counteracted with diet and exercise, NASH 
is less reversible, and researching potential treatments with rising incidence levels is 
important (Oseini and Sanyal, 2017). One of the potential treatment options being researched 
for NASH is cannabinoids, as there are endogenous cannabinoid receptors in the liver that 
are expressed by immune cells that can be targeted to slow hepatic fibrosis (Caraceni et al., 
2014).  Mast cells are an important part of the body’s immune response to damage, and their 
numbers in liver hepatocytes directly correlate to fibrosis levels in NASH (Lombardo et al., 
2018). My research aims to evaluate the infiltration of mast cells in Methionine/Choline 
deficient (MCD) diet induced mouse MASH models and observe any changes that may result 
from treatment with high and low levels of cannabigerol (CBG).  
Review of Relevant Literature 
Mast Cells 
 Mast cells were originally viewed as allergy effectors, playing an important role in 
allergic reactions, and when being studied in 1878, could only be identified by their 
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morphological features (da Silva et al., 2014). As technology improved, mast cells were 
found to release histamine during anaphylactic shock, triggered by the presence of IgE 
antibodies that bind to receptors on the mast cell surface (da Silva, 2014). Derived from 
hematopoietic stem cells, mast cells are distributed to tissues of high vascularization and 
surfaces exposed to external environments (Galli, Nakae, and Tsai, 2005). Therefore, they 
are the first immune cells to interact with any released antigens, allergens, or pathogens, 
leading to the release of bioactivators which can mediate the effects of inflammation, anti-
inflammation, or immunoregulation and more (Galli or Tsai, 2005). These mediators are 
stored in the granules of mast cells and can be released upon fusion to plasma membranes 
and extrusion of the granules into the tissue (da Silva et al., 2014).  
In response to allergens, mast cells activate FcɛRI which leads to protein 
phosphorylation, intracellular calcium mobilization, lipid metabolism and phosphorylation, 
and the activation of transcription factors (TF). Activating TF’s can stimulate cytokine and 
chemokine production to influence inflammation, increase vascular permeability, initiate 
smooth muscle contraction, mucus secretion, and/or edema (da Silva et al., 2014).  Pathogens 
can bind directly to the mast cells, initiating granule release, contributing to innate immunity, 
and supporting adaptive immunity (da Silva et al., 2014; Galli, Nakae, and Tsai, 2005). Mast 
cells enhance the recruitment of T-cells and initiate lymph node enlargement to avoid harm 
caused by the invaders (Galli and Nakae, 2003). By enlarging the lymph nodes, lymphocytes, 
T-cells, and antigen-presenting cells are collected and drained, aiding in adaptive immune 
response (McLachlan et al., 2003).  
Mast cells also have important function in the maintenance of homeostasis and tissue 
repair. Certain mediators released by mast cells are growth factors which can initiate 
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proliferation of epithelial cells, endothelial cells, and fibroblasts, potentially remodeling 
tissue (da Silva et al., 2014; Galli and Nakae, 2003). The most common example of mast 
cells remodeling tissue is airway remodeling due to asthma, where changes are made to 
bronchial microvasculature, altering basement membrane thickness, hypersecretion of mucus 
and regulation of profibrotic growth factors (Hong, Kim, and Ro, 2014).  
Tissue remodeling and other pathways regulated by mast cells can have a pathologic 
effect, resulting in harmful consequences to an organism, such as chronic inflammation in 
Crohn’s disease, innate immune response towards own cells in autoimmune diseases, 
mastocytosis caused by the mutation of mast cells and released mediators, and even cancer as 
a result of tumor formation via tissue remodeling (da Silva et al., 2014; Williams and Galli, 
2000; Maltby, Khazaie, and McNagy, 2009).  
NAFLD and NASH  
 NAFLD has been on the rise in many westerns and Asian countries due to changes in 
lifestyle and diet, increasing the potential development of hepatocellular carcinoma 
(Hashimoto et al., 2015; Yu, 2018). The disease is characterized by rapid weight gain, the 
accumulation of fat in pathological amounts, and varying stages of fibrosis (Sanyal, 2011). 
Its classification relies on the alcohol consumption of the individual, classifying as non-
alcoholic if less than 20-30g of alcohol is consumed per day (Hashimoto et al., 2015; Sanyal, 
2011).  Risk factors associated with NAFLD include obesity, diabetes, insulin resistance, 
hypertension, low levels of high density lipoprotein (HDL) cholesterol, or dyslipidemia (Yu, 
2018). The risk is higher when these occur simultaneously in an individual and can be 
influenced by diet. Polyunsaturated fatty acids (PUFAs) have pro- and anti-inflammatory 
effects. Altered ratios of these PUFAs are associated with the development of NAFLD due to 
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excess fatty acids, and their manipulation by diet is used for treatment (Wree et al., 2013; 
Oseini and Sanyal, 2016). However, continued diet with altered PUFA ratios can advance 
NAFLD to NASH (Wree et al., 2013). Excess consumption of fructose also influences 
NAFLD development, as it is lipogenic and increases triglyceride formation in the liver 
(Wree et al., 2013; Oseini and Sanyal, 2016). Age, genetics, gender, and ethnicity are also 
risk factors in NAFLD development, Hispanic’s having the highest prevalence and African 
Americans having the lowest (Yu, 2018).  
 NASH is the advanced stage of NAFLD, characterized by cell injury and fibrosis, 
occurring in 30-80% of NAFLD patients (Yu, 2018; Sanyal, 2011). It is expected to become 
the leading cause for liver transplantation in the US, passing hepatitis C virus infection 
(Oseini and Sanyal, 2016). High levels of scarring from NASH can cause cirrhosis, 
increasing chances of HCC development (Eguchi et al., 2021). With such high NAFLD and 
NASH incidence rates, HCC is now the fifth most common cancer among males globally 
with 0.5-2.3% of NALFD patients developing the cancer (Eguchi et al., 2021; Yu 2018). 
NASH also independently increases risk of cardiovascular mortality, particularly in adults 
with type 2 diabetes, due to the effect of the excess adipose on glucose and lipid metabolism 
(Targher et al., 2007; Sanyal, 2011; Lim and Meigs, 2014).  
 Treatment for NAFLD and NASH begins with changes to diet and lifestyle, such as 
losing weight, exercising regularly, and restricting calorie intake (Oseini and Sanyal, 2016; 
Yu, 2018). Pharmaceutical options include peroxisome proliferator-activator receptor 
(PPAR) agonists, synthetic bile farnesoid X receptor (FXP) agonists, lipid altering agents, 
incretin-based therapy, antifibrotic therapy, microbiome therapy, and agents that target 
inflammation, cell injury, apoptosis, and oxidative stress, such as Vitamin E (Oseini and 
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Sanyal, 2016). Vitamin E is used first when diet and exercise yield little results, reducing 
steatosis, inflammation, and alanine aminotransferase levels (Oseini and Sanyal, 2016; 
Sanyal et al., 2010). PPAR agonists target PPAR receptors which regulate metabolic 
processes such as β-oxidation, gluconeogenesis, and lipid transport. A PPARα/δ agonist has 
shown promise in NASH treatment, improving hepatic insulin sensitivity, and in some cases, 
resolving NASH cases with no cirrhosis (Oseini and Sanyal, 2016). One study found that a 
PPARγ/α agonist was effective in NASH treatment of fructose induced rats, inducing effects 
on gene expression responsible for insulin resistance, fibrosis, and the synthesis of fatty acids 
(Abd El-Haleim et al., 2016).  
Role of Mast Cells in NAFLD and NASH  
  NALFD an NASH induce hepatic injuries, damaging hepatocytes and recruiting mast 
cells as part of the immune response (Jarido et al., 2017). Mast cells were initially not 
thought to play a role in liver fibrosis (Sugihara et al., 1999). Multiple studies have since 
determined that mast cell numbers correlate directly to levels of fibrosis in NASH as they are 
mediators of inflammation (Lombardo et al., 2018; Lewandowska et al., 2020). In human and 
rodent livers, mast cells are mainly associated with connective tissue that is found by arteries, 
veins, and bile ducts, particularly those that have been injured (Jarido et al., 2017; Kennedy 
et al., 2021). Infiltration by mast cells is preceded by proliferation of cholangiocytes, which 
are cells that line biliary tracts (Kennedy et al., 2021). Mast cells and cholangiocytes are 
thought to regulate one another, and chronic inflammation of cholangiocytes can lead to 




Mast cells release mediators into the liver in response to proinflammatory cytokines, 
adipokines, oxidative stress, endoplasmic reticulum stress, mitochondrial dysfunction, and 
other damage factors (Jarido et al., 2017; Lewandowska et al., 2020). Mediators released 
include histamine, tryptase, heparin, cytokines, TGF-β1, vascular endothelial growth factor, 
and many fibroblast growth factors (bFGF and FGF), which contribute to fibrosis (Jarido et 
al., 2017; Lewandowska et al., 2020). As NAFLD progresses to NASH, higher levels of mast 
cells were recorded, directly affecting levels of fibrosis in patients (Lewandowska et al., 
2020). A study that observed mast cell deficient mice reintroduced to mast cells displayed 
higher levels of fibrosis, and that inhibiting mast cell mediators can reduce levels of fibrosis 
(Kyritsi et al., 2020).  
The growth factor TGF-β1 is an anti-inflammatory cytokine that is secreted from 
mast cells upon activation of the FcɛRI receptors (Lyons et al., 2018). It initiates damage 
pathways that lead to hepatic fibrosis, biliary senescence, and biliary angiogenesis (Kyritsi et 
al., 2020). Through the activation of hepatic stellate cells (HSC), TGF-β1 imitates HSC 
proliferation and the production of collagen and other extracellular matrix proteins (Kiss et 
al., 2018).   
Therapeutic Role of CBG 
 Cannabigerol (CBG) is a Cannabis Sativa terpenophenol, utilizing a similar 
mechanism of action to cannabidiol (CBD), that is being explored as a medical treatment for 
many different diseases (Giacomo et al., 2020). CBG acts as a competitive partial agonist to 
CB2 receptors and binds to the orthosteric center of CB1 receptors, effectively acting as a 
regulator for endocannabinoid receptors (Navarro  et al., 2018). These receptors are located 
throughout the body at different concentrations, and CB2 receptors are expressed on immune 
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cells (Caraceni et al., 2014).  CBG has been found to use antiproliferative, antibacterial, and 
anti-glaucoma actions, displaying potential therapeutic effects on neurodegenerative diseases, 
similar to CBD which has been widely studied (Borrelli et al., 2013; Giacomo et al., 2020).  
A CBG derivative, VCE-003.2, was observed to improve antioxidant brain responses 
and inhibit proinflammatory marker upregulation in Huntington’s disease, alleviating 
symptoms and preventing neuronal loss (Diaz-Alonso et al, 2016). Mice models in a study 
using VCE-003.2 had improved motor performance, less neuron damage from Huntington 
disease induced mutations, and reduced inflammation under the CBG treatment (Aguareles et 
al., 2019). When exploring neuroprotective and antioxidant effects of cannabinoids on 
astrocytes, CBG was found to decrease apoptosis occurrence due to oxidative stress and 
prevent serotonin depletion (Giacomo et al., 2020). CBG has shown to enact neuroprotective 
effects and decrease levels of neuroinflammation and oxidative stress, making CBG a 
promising drug for other diseases in the body (Gugliandolo et al., 2018).  
Diseases in the gastrointestinal tract and liver have been targeted using cannabinoids 
as the endocannabinoid system has been detected in both humans and mice (Caraceni et al., 
2014). CBD and THC were found to have many beneficial effects on diseases such as 
irritable bowel syndrome (IBS) and GERD (Caraceni et al., 2014). When CBG was used for 
IBS treatment, nitric oxide production from macrophages and reactive oxygen species 
formation in intestinal epithelial cells was reduced, potentially relieving IBS symptoms and 






 This study was conducted at the University of Northern Colorado in the Department 
of Biology and the School of Biological Sciences. 8 week old C57BL/6 mice were fed a 
methionine/choline deficient (MCD) diet to induce NASH or a control (CTR) diet 3 times per 
week for 3 weeks. Then the mice were divided into 3 experimental subgroups for each diet. 
Mice were then injected with vehicle, high CBG [24.6 mg/kg/day] or low CBG [2.46 
mg/kg/day] for 2 weeks while being fed the same diets. The mice were sacrificed, and their 
livers were harvested and frozen for further experimentation. This was conducted with 6 
male mice and 4 female mice for each treatment group.  
Slide Preparation  
 For preparation of the frozen slides, the mouse livers were stored at -80°C embedded 
in tissue freezing media. Slices were sectioned at 8µm using a cryostat microtome at -20°C. 
The slides were stored at the same temperatures as the livers.  
 For preparation of paraffin slides, the mouse livers were fixed in 10% formalin for 24 
hours, then sent to a commercially available company for tissue processing, wax embedding, 
cutting and slide placement (iHisto Inc., CA). The slides were then sent back for staining use.  
Toluidine Blue Staining  
 Slides with sections of frozen liver were stained with T-blue to attempt visualization 
of mast cells. The toluidine blue stain was used and prepared according to the provided 
protocol. Slides were fixed in neutral buffered formalin (NBF), dipped in HCl for 10 
seconds, stained for 30 seconds, dipped in increasing isopropanol concentrations, then dipped 
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in Xylene as the clearing agent. The slides were mounted with a non-aqueous mounting 
media and observed under the microscope.  
Chloroacetate Esterase Staining  
 Frozen slides and paraffin slides were stained using CAE staining. The Sigma-
Aldrich Naphthol AS-D Chloroacetate Esterase staining kit was used, and the stain was 
prepared according to provided protocol. Frozen slides were fixed according to protocol, then 
stained with the CAE solution for 15 minutes at 37°C incubation, and counterstained with 
hematoxylin for 30 seconds. Paraffin slides had to be dewaxed prior to staining. No fixation 
was necessary. Slides were heated to 55°C for 5 minutes, dipped in 2 separate fresh xylene 
solutions, dipped in isopropanol of descending concentrations, and rinsed with distilled 
water. Staining protocol was followed with alteration to the staining times. The slides were 
incubated with the CAE solution for 30 minutes, then counterstained for 1 minute. Both 
frozen and paraffin slides were mounted with aqueous mounting media and observed under 
the microscope. For best results, slides should never dry during entire staining process until 
mounted.  
FcɛR1/TGFβ1 Staining  
 The FcɛR1 antibody used was conjugated, already containing fluorescent dye. It was 
used with a dilution of 1:50. The TGFβ1 antibody was unconjugated, so a second staining 
step with fluorescent dye was performed. It was used at a dilution of 1:100. Frozen liver 
slides were fixed with 10% NBF for 10 minutes, then treated with 10% goat serum diluted in 
PBS to block the FC domain and incubated for 20 minutes at room temperature. Slides were 
washed with 1X PBS in between each step. The two antibodies were mixed together in 1% 
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goat serum and 100 µL of the mixture was applied to each slide followed by overnight 
incubation at 4°C. The following day, the secondary antibody was mixed in 1% goat serum 
and slides were stained with the mixture for 1 hour at room temperature in a dark 
environment. The slides were mounted with DAPI mounting media and observed using a 
confocal microscope.  
Statistical Analysis   
 Mast cells were quantified by counting visualized mast cells from photos taken 
through the microscope using CAE slides. Mast cell counts were compared between MCD 
and CTR groups, and between low CBG and high CBG groups. A one-way ANOVA was 
used for comparing the experimental groups. Once the differences were determined, the 
appropriate post-hoc analysis was performed using two-tailed t-tests. Values where p<0.05 
were treated as significant.  
Results  
Toluidine Blue Staining  
 The desired results of the T-blue staining were not achieved. There was poor 
visualization of any mast cells and differentiation from artifacts was difficult. This can be 
seen in Figure 1. Tissue morphology was poor and there were inconsistencies of stain 




Figure 1 - Results from T-blue staining of frozen slides. Mast cells were not visualized with 
T-blue staining in mouse tissue.  
Chloroacetate Esterase Staining  
 Frozen slides stained in CAE had poor tissue morphology, making mast cell 
visualization difficult. Using paraffin slides solved that issue and mast cells were easily 
visible. As shown in Figure 2, there were no mast cells observed in the CTR group, as there 
was no induced liver disease in the mice. There were higher levels of mast cells in the MCD-
fed groups. The highest occurrence of mast cells was found in the control group treated with 
vehicle. There were also higher visual levels of fat deposition in the hepatocytes present in 
the tissue. Mast cells were observed in the CBG treatment groups but at lower amounts. 
There were less mast cells and visible fat deposition in the low CBG group compared to the 
high CBG group. There were higher visual levels of fat deposition in the high CBG group 
compared to the low CBG group. Figure 3 visualizes the average number of mast cell counts 
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found in the MCD livers. A trend of differences was found between vehicle and both CBG 
groups. There was no trend of differences between the low CBG and high CBG groups. 
 
Figure 2 - Results from the CAE staining of paraffin slides. Liver samples were from female 
mice. Arrows point to mast cells found within the hepatic tissue. No mast cells were 
observed in the CTR group, and the highest mast cell counts were observed in the MCD-fed 
vehicle treatment group. Lowest mast cell numbers were observed in the MCD-fed low CBG 





Figure 3 - Quantification of mast cells within the CAE stained MCD-fed treatment groups. 
Highest mast cell numbers were found in the vehicle control group, while lowest numbers 
were found in the low CBG group. Quantification was calculated based on 12 randomly 
selected fields per treatment group, n=1 for each treatment. Values are expressed as means 
±SD.  
FcɛR1/TGFβ1 Staining  
 Immunofluorescence staining using FcɛR1/TGFβ1 antibodies yeilded similar results 
to the CAE staining. There were no mast cells present in the CTR groups, with the exception 
of two areas of colocalization which were determined to be insignificant. Red 
immunofluoresence indicates the presence of mast cells. Figure 4 shows that mast cells were 
mostly present in the vehicle MCD group. There were almost no mast cells present in the low 
CBG group. There were higher levels of mast cells in the high CBG group compared to the 
low CBG. Green immunofluoresence indicates the presence of TGFβ1 and areas of 






























high colocalization in the high CBG treatment group. Low levels of cololcalization were seen 
in the veichle MCD group, and even less were observed in the low CBG treatment group.  
 
Figure 4 -  Results from the FcɛR1/TGFβ1 Immunofluorescence. Liver samples were from 
male mice. Red indicates FcɛR1 positive staining (mast cell marker). Green indicates TGFβ1 
positive staining. Arrows point to colocalization, indicating presence of mast cells expressing 
TGFβ1. Blue indicates hepatocyte nuclei, stained with DAPI.  
Discussion  
 Mast cells were not observed under the CTR diet. They were observed under the 
MCD diet in high amounts with no treatment. The CAE staining showed that mast cell 
infiltration in the MCD groups did change under CBG treatment, decreasing the most under 
low CBG treatment. While mast cell infiltration also decreased under high CBG treatment, 
high levels of fat deposition in the hepatocytes was still observed inferring that low CBG had 
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the best effect on reducing mast cell numbers, aiding in the potential reversal of NASH. The 
results from the FcɛR1/TGFβ1 immunofluorescence co-staining also showed that mast cell 
infiltration in the MCD groups decreased the most under low CBG. While there were lower 
levels of mast cells under high CBG compared to the vehicle group, the mast cells were 
expressing higher levels of TGFβ1, indicating that TGFβ1-dependent fibrosis may still be 
occuring under the high CBG treatment. The low levels of mast cell TGFβ1 expression under 
low CBG supports potential NASH reversal as seen with lower fat deposition presence under 
CAE staining.  
 The lower levels of fat deposition, decreased infiltration of mast cells, and decreased 
evidence of mast cell TGFβ1 expression under low CBG indicates that it is a viable treatment 
for NASH in MCD induced mice models. It has the potential to reverse the effects of NASH 
and aid in NAFLD treatment.  
 Of the methods used, CAE staining and immunofluorescence co-staining were the 
most functional methods, providing observable data. CAE staining worked best with paraffin 
slides, as they provided the clearest morphology under the microscope. It was crucial to keep 
the slides wet throughout the de-waxing and staining process for the best results. However, 
the mast cells were easier to visualize when stained with immunofluorescent protein. Co-
staining allowed us to see where mast cells were activated, which CAE staining could not 
show us. Immunofluorescence provided the best information regarding the levels of mast 
cells in the tissue, while CAE staining provided the best information regarding changes in 
morphology, such as fat deposition in the tissue.  
 Future steps in this research include study replication with a larger sample size, 
further exploration of CBG’s role in NASH reversal in multiple different models, and 
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exploration of off-target effects and other effects of long term CBG usage. CBG treatment 
has shown potential in neurodegenerative diseases, and now shows potential in hepatic 
diseases as well. With incidence rates of NAFLD and NASH rising, discovering treatment 
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